| Autor: |
Sayah N; Department of Cardiology, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, 46 Rue Henri Huchard, 75018 Paris, France., Bhatt DL; Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai Health, New York, NY, USA., Miller M; Department of Medicine, Crescenz Veterans Affairs Medical Center and University of Pennsylvania School of Medicine, Philadelphia, PA, USA., Brinton EA; Utah Lipid Center, Salt Lake City, UT, USA., Jacobson TA; Lipid Clinic and Cardiovascular Risk Reduction Program, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA., Ketchum SB; Amarin Pharma, Inc. (Amarin), Bridgewater, NJ, USA., Jiao L; Amarin Pharma, Inc. (Amarin), Bridgewater, NJ, USA., Pineda AL; Amarin Pharma, Inc. (Amarin), Bridgewater, NJ, USA., Doyle RT Jr; Amarin Pharma, Inc. (Amarin), Bridgewater, NJ, USA., Tardif JC; Montreal Heart Institute, Université de Montréal, Montreal, Québec, Canada., Ballantyne CM; Department of Medicine, Baylor College of Medicine, and the Texas Heart Institute, Houston, TX, USA., Steg PG; Department of Cardiology, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, 46 Rue Henri Huchard, 75018 Paris, France.; FACT (French Alliance for Cardiovascular Trials), Assistance Publique-Hôpitaux de Paris, INSERM Unité 1148, Université Paris-Cité, Hôpital Bichat, Paris, France. |
